Circulating AIM as an Indicator of Liver Damage and Hepatocellular Carcinoma in Humans-Reference-Cited by-同舟云学术

Circulating AIM as an Indicator of Liver Damage and Hepatocellular Carcinoma in Humans

Published:2014-10-10 Issue:10 Volume:9 Page:e109123
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yamazaki Tomoko,Mori Mayumi,Arai Satoko,Tateishi Ryosuke,Abe Masanori,Ban Mihoko,Nishijima Akemi,Maeda Maki,Asano Takeharu,Kai Toshihiro,Izumino Kiyohiro,Takahashi Jun,Aoyama Kayo,Harada Sei,Takebayashi Toru,Gunji Toshiaki,Ohnishi Shin,Seto Shinji,Yoshida Yukio,Hiasa Yoichi,Koike Kazuhiko,Yamamura Ken-ichi,Inoue Ken-ichiro,Miyazaki Toru

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference48 articles.

1. Global cancer statistics;A Jemal;CA Cancer J Clin,2011

2. Epidemiology of hepatocellular carcinoma;FX Bosch;Clin Liver Dis,2005

3. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis;HB El-Serag;Gastroenterology,2007

4. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace;G Baffy;J Hepatol,2012

5. Nonalcoholic fatty liver disease;P Angulo;N Engl J Med,2002

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD5L as a promising biological therapeutic for treating sepsis;Nature Communications;2024-05-15

2. Apoptosis inhibitor of macrophage (AIM)/CD5L is involved in the pathogenesis of COPD;Respiratory Research;2023-08-17

3. The comprehensive role of apoptosis inhibitor of macrophage (AIM) in pathological conditions;Clinical and Experimental Immunology;2022-11-25

4. Serum levels of immunoglobulin M‐free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis‐associated hepatocellular carcinoma;Hepatology Research;2022-08-28

5. The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective;Frontiers in Medicine;2022-06-24